Price: $9.46
· 1 day: -6.24% · 5 days: -0.73% · 1 month: +10.77% · YTD: -17.24%
As of 2026-11-06 21:00 UTC.
52-week range: $8.13 – $14.76 (currently at 20% of the range).
XRAY is in a downtrend, momentum firm. $9.6 is the level overhead; $9.41 the first support below.
4 of 6 technical checks lean bearish.
| Trend | Downtrend · below 50-day & below 200-day |
|---|---|
| Momentum | RSI 49.6 · neutral · MACD bullish |
| Trend strength | ADX 29.0 · strong trend |
| Location | -1.5% vs 50-day MA |
| 52-week range | -36% from high · +12% from low |
| Volatility | ATR 0.53 · ~5.6%/day |
| Level | Type | Distance |
|---|---|---|
| $9.6 (resistance) | sma 50 | 1.48% |
| $10.0 (resistance) | round | 5.71% |
| $10.64 (resistance) | swing zone | 12.47% |
| $9.41 (support) | swing zone | -0.53% |
| $9.0 (support) | round | -4.86% |
| $8.42 (support) | 52w low | -10.99% |
| RSI (14) | 49.6 | MACD | 0.1526 |
|---|---|---|---|
| ADX (14) | 29.0 | ATR (14) | 0.53 |
| 50-day average | $9.6 | 200-day average | $11.27 |
Next earnings: 2026-11-05. XRAY earnings date, time and past reactions.
Report of 2026-11-05.
XRAY has surged 11.9% over the past five trading days to $10.75, outpacing both the S&P 500 by 10.4 percentage points over 50 days and the healthcare sector by 6.3 percentage points over five days — yet the weekly trend remains down, price sits below its 40-week average, and the 14-day RSI reads 80.79, marking overbought territory in a pullback that has now run far enough to test the next layer of resistance. The balance of evidence leans negative over the next two to six weeks, though conviction is low because the stock has defied the broader market's direction for a month.
The five-day attribution拆解 shows the stock's move was not purely a sector story. XLV gained 5.5% over the same span while SPY fell 0.7%, yet XRAY added 11.9% — roughly six percentage points of outperformance against the healthcare sector alone. That divergence suggests either a stock-specific catalyst or a short-covering dynamic that has run its course. The most concrete recent news is a legal investigation announced October 27 by Halper Sadeh LLC, an investor rights law firm examining whether DENTSPLY SIRONA officers and directors breached fiduciary duties to shareholders, focusing on corporate governance issues and potential misconduct that may have harmed long-term holders. The firm is encouraging investors to come forward, per the PR Newswire report. That investigation does not yet have a resolution, but it adds a governance overhang to a stock already trading near the bottom of its 52-week range, 26.8% below the $14.68 high and 27.7% above the $8.42 low.
Earlier in October, the company filed an 8-K disclosing entry into a material agreement and the creation of a material financial obligation, per SEC EDGAR. The filing did not specify the terms, leaving the market to price uncertainty. Against this backdrop, the analyst consensus sits at hold across 15 estimates, with a mean price target of $12.40 — roughly 13.3% above the current price — and a range running from $9.00 to $17.00. The wide spread reflects genuine disagreement about fair value, not a clear directional conviction from the sell side.
The stock's one-month gain of 26.2% is the sharpest move in the data set, but it follows a six-month decline of 5.5% and a year-to-date loss of 5.9%. The year-to-date performance also trails SPY by over 18 percentage points, meaning the stock has been a consistent underperformer in 2026 even before the recent snap-back. The debate in the market is whether this five-day surge marks a genuine trend change or a bear-market rally that will fade once the overbought reading resolves.
The long-term thesis is intact but not improving. The weekly trend is down: price closed below its 40-week average, and the 200-day simple moving average at $11.29 sits above the current price. The stock has spent most of the past year in a declining channel, carving a 52-week high of $14.68 in early 2026 and a low of $8.42. The recent rally has moved the stock back toward the middle of that range without breaking the structural downtrend. This is a pullback within a downtrend, not a new uptrend — the distinction matters for position management.
Over the next two to six weeks, the balance of evidence leans negative. The 14-day RSI at 80.79 is the most immediate technical signal: the rally has extended far enough to attract selling. The stock is approaching the $11.00 round number, which has acted as resistance on prior rallies and aligns with the 200-day average at $11.29. Volume over the past 20 days has been 98.4% below average, suggesting the move lacks broad institutional conviction. The attribution data confirms this: the stock led both the market and the sector over five days, which is unusual breadth for a stock in a confirmed downtrend and often precedes a reversal. Conviction is low — one of four points — because the stock has been resilient against the trend for a month, and overbought readings can persist longer than fundamentals suggest.
The strongest case against the bearish reading is that XLV has gained 13.3% over one month, suggesting the healthcare sector has momentum that could carry XRAY higher regardless of its individual chart. The analyst mean target of $12.40 also sits above the current price, implying 13% upside from here. The stock has gained 26% in one month, which demonstrates it can move fast. None of these arguments tip the balance because the weekly trend is the dominant frame, the RSI is extreme, and the volume profile confirms the move is not broadly supported — the sector tailwind explains part of the gain but not the full 11.9% over five days.
The structure holds below $11.00. That round number has acted as a ceiling on three separate rallies in 2026, and it aligns closely with the 200-day average at $11.29. The $12.38 swing zone is where the prior downtrend would end: a weekly close above that level would mark the first genuine break of the lower-high pattern that has defined the stock's decline. Below, the $10.64 swing zone is the nearest support, followed by the 50-day average at $9.65 and the $9.41 swing zone below that.
The breakout math points to a downside scenario. A daily close below $10.64 would open the $9.65 and $9.41 targets, giving reward-to-risk ratios of 2.2 and 2.7 against a stop at $11.09 (the $11.00 round number plus a quarter of the 14-day ATR of $0.37). The math does not reach the 3-to-1 threshold that would make a breakout trade compelling on its own. To change that math, the stock would need to approach the $9.00 round number — adding roughly 70 cents of additional downside — which would lift the reward-to-risk closer to 3 to 1 from the $10.64 breakout level. The map is defined; the reader decides how to navigate it.
A weekly close above $12.38 — the swing zone that marked the prior reaction low — would be the level where the downtrend ends and the picture shifts from pullback to potential trend reversal. That is the structural rule. The one non-price fact that would do it is a resolution of the Halper Sadeh fiduciary investigation: if the inquiry clears current management or reveals a concrete remediation plan, the governance overhang lifts and the stock could re-rate toward the analyst mean target of $12.40 without waiting for a technical break above $12.38.
Interactive XRAY chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs